MTOR and tuberous sclerosis: Recent research has helped us understand the pathophysiology of TSC, which has led to the use of mTOR inhibitors for the treatment of certain manifestations of TSC including subependymal giant cell astrocytomas (SEGAs) and renal angiomyolipomas [7–10].